Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of toosendanin (TSN)-treated DLBCL cells

ABSTRACT: Transcriptome analysis of toosendanin (TSN)-treated DLBCL cells

PROVIDER: PRJNA1130884 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR29679100_1.fastq.gz	Fastqsanger.gz
	SRR29679100_2.fastq.gz	Fastqsanger.gz
	SRR29679093_1.fastq.gz	Fastqsanger.gz
	SRR29679093_2.fastq.gz	Fastqsanger.gz
	SRR29679094_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Transcriptome analysis of toosendanin (TSN)-treated macrophages

Project description:Transcriptome analysis of toosendanin (TSN)-treated macrophages

| PRJNA804920 | ENA

Transcriptome analysis in Neobractatin treated cells

Project description:Transcriptome analysis in Neobractatin treated cells

| PRJNA428359 | ENA

Transcriptome analysis for vorinostat-treated choriocarcinoma cells

Project description:Transcriptome analysis for vorinostat-treated choriocarcinoma cells

| PRJNA791536 | ENA

DLBCL

Project description:DLBCL

| PRJNA1118307 | ENA

Sequencing analysis of CAR T cell products and apheresis cells in DLBCL patients treated with tandemCAR-T cell

Project description:In this study, 58 r/r DLBCL patients treated with tandem CD19/CD20 CAR T cells. Twenty-seven patients had durational responses for more than 24 months, and the median PFS was 21.7 months. But 15 patients still did not have an objective response, and 11 patients relapsed within 1 year. The analysis found that CD8+TSCM cells with higher frequency and stronger activation ability in CART products were the key to achieving clinical sustained objective response. Bulk RNA-Seq and single-cell RNA-Seq then were performed on CAR-T cell products and pre-manufacture T cells of patients with DLBCL. We note that a CD8+ stem cell-like memory T cell population with a higher proportion and stronger activating capacity of the CAR-T cell products was key to achieving durable clinical response. By analyzing autologously-derived, pre-manufacture T cells, our data suggest that heterogeneity in the cellular and molecular features of pre-manufacture T cells contribute to the variation in efficacy after CAR-T cell therapy in DLBCL. The differences in anti-tumour efficacy of CAR-T cells among patients with different clinical outcomes appear to be due to the loss of CCR7 gene expression accompanied by increased expression of activation- and inhibitor-related genes in the CD8+ naïve-T cell populations among the apheresis T cells from patients with a poor molecular response. These findings significantly advance our understanding of the underlying molecular determinants of pre-manufacture T cell function.

2023-11-09 | GSE243325 | GEO

Sequencing analysis of CAR T cell products and apheresis cells in DLBCL patients treated with tandemCAR-T cell

Project description:Sequencing analysis of CAR T cell products and apheresis cells in DLBCL patients treated with tandemCAR-T cell

| PRJNA1017828 | ENA

DLBCL patients

Project description:DLBCL patients

| PRJNA613053 | ENA

RNA sequencing results of treatment with BET inhibitor (JQ1) in human diffuse large B-cell lymphoma (DLBCL) cells based on Illumina HiSeq 2500 platform

Project description:High-throughput RNA sequencing Analysis of human diffuse large B-cell lymphoma (DLBCL) cells treated with BET inhibitor. Our study represents the detailed analysis of the more accurate quantitative and qualitative evaluation of mRNA content within DBLBC cells. Our study represents the detailed analysis of the more accurate quantitative and qualitative evaluation of mRNA content within DLBCL cells.

2022-03-01 | GSE144821 | GEO

Genome-wide Gene Expression Profiling in DLBCL Cell Lines Treated with CUDC-907

Project description:CUDC-907 is a small-molecule dual-acting inhibitor of HDACs and PI3Ks, which effectively suppresses the growth and survival of MYC-altered DLBCL. To evaluate the effect of CUDC-907 on MYC-associated genes, two DLBCL cell lines were treated with CUDC-907, a total of 948 differentially regulated genes were identified. 24 genes from the CUDC-907–regulated 948-gene set present either in the "HALLMARK_MYC_TARGETS_V1” 200-gene set or in the “HALLMARK_MYC_TARGETS_V2” 58-gene set in the Molecular Signatures Database (MSigDB). We then computed the correlation coefficients (r) between gene expression levels and MYC protein levels across all samples in the TCGA DLBCL dataset. We found that mRNA expression changes induced by CUDC-907 in the two DLBCL cell lines are negatively correlated with correlation coefficients between expression levels and MYC protein level in the TCGA DLBCL dataset

2016-11-02 | GSE89339 | GEO

RNA-Seq analysis of DLBCL cell lines

Project description:RNA-Seq analysis of DLBCL cell lines

| PRJNA854968 | ENA